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Fibroblast growth factor (FGF) family members are mostly secreted as signaling proteins
with diverse functions in development and metabolism. FGF21 is a unique FGF with meta-
bolic, but not proliferative activities. FGF21 is mostly induced by different kinds of stress
and acts though FGF receptor 1c with β-Klotho as a cofactor in an endocrine or, in parts,
autocrine/paracrine manner. Hepatic FGF21 directly acts on white adipocytes to inhibit
lipolysis and acts through the brain to increase systemic glucocorticoid levels and suppress
physical activity in response to starvation. It also protects against dioxin toxicity. Adipocytic
FGF21 induces the browning of white adipose tissue (WAT) and activates brown adipocytes
in response to cold exposure. It also acts as an upstream effector of adiponectin in white
adipocytes. Myocytic FGF21 protects against diet-induced obesity and insulin resistance,
induces the browning of WAT, and protects against cardiac hypertrophy. In addition, Fgf21
polymorphisms are possibly related with metabolic diseases and FGF21 are biomarker
of metabolic diseases. These findings indicate that FGF21 plays roles as a hepatokine,
adipokine, and myokine in metabolism, injury protection, and diseases.
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INTRODUCTION
Fibroblast growth factors (FGFs) are signaling proteins of ~150–
300 amino acids with diverse biological functions mainly in
development and metabolism. The human/mouse FGF family
comprises FGF1–FGF23. However, as mouse FGF15 and human
FGF19 are orthologs, they are usually referred to as FGF15/19 (1).
FGFs can be classified into paracrine, intracrine, and endocrine
FGFs based on their mechanisms of action. Paracrine FGFs mainly
function as secreted local signaling molecules in development.
Endocrine FGFs mainly function as hormone-like or, in parts,
local signaling molecules in metabolism. In contrast, intracrine
FGFs mainly function as intracellular molecules in neuronal
processes (1).
Endocrine FGFs comprise FGF15/19, FGF21, and FGF23 (1).
Although most of paracrine and endocrine FGFs have proliferative
activities, FGF21 is a unique FGF with metabolic, but not pro-
liferative activities. FGF21 exerts diverse pharmacological effects
on metabolism. Review articles that focus on its pharmacological
effects and therapeutic uses for metabolic diseases have already
been published (2, 3). This succinct review focuses on the phys-
iological and pathophysiological roles of FGF21 as a metabolic
regulator.
MECHANISM OF ACTION OF FGF21
Paracrine and endocrine FGF signaling is mostly mediated by
the activation of FGF receptors (FGFRs) including FGFRs 1b,
1c, 2b, 2c, 3b, 3c, and 4 with different ligand-binding speci-
ficities. FGFs activate four key intracellular signaling pathways:
RAS/RAF/mitogen-activation protein kinase (MAPK), phos-
phatidylinositol 3-kinase (PI3K)/serine–threonine protein kinase
AKT, signal transducer and activator of transcription (STAT), and
phosphoinositide phospholipase C (PLC) γ (1). Endocrine FGFs
activate FGFRs with α-Klotho or β-Klotho as a cofactor, which are
specifically expressed in their targeted tissues (1). FGF21 activates
FGFR1c with β-Klotho (1, 4).
FGF21 AS A HEPATOKINE
Fgf21 is abundantly expressed in the liver. Hepatic Fgf21 expres-
sion was possibly induced during fasting through the activation
of peroxisome proliferator-activated receptor (PPAR) α by non-
esterified fatty acids that are released from adipocytes and taken up
by hepatocytes (5). Lipolysis was increased in the white adipocytes
of fasted Fgf21 knockout mice, indicating that FGF21 inhibit lipol-
ysis during fasting (Table 1) (6). A low-carbohydrate, high-fat
ketogenic diet (KD) significantly induced hepatic Fgf21 expres-
sion. The impaired insulin sensitivity in WAT caused by KD
feeding was improved in the knockout mice, indicating that FGF21
is a negative regulator of adipocyte insulin sensitivity in adapta-
tion to a low-carbohydrate malnutritional state (7). FGF21 also
increased systemic glucocorticoid levels and suppressed physical
activity in adaptation to the starvation response. Mice lacking
β-Klotho in the suprachiasmatic nucleus and dorsal vagal com-
plex of the brain were refractory to these effects. Thus, hepatic
FGF21 also exerts diverse actions through β-Klotho in the brain
(Table 1) (8).
In addition to fasting and KD, hepatic Fgf21 expression was
significantly induced by different kinds of stress such as hepatic
injury, chemical insult, and diseases. Hepatic FGF21 is a stress-
induced metabolic regulator (19). The toxicity of dioxins is also
well documented. Dioxins increased hepatic Fgf21 expression and
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Table 1 | Functions of FGF21 as a hepatokine, adipokine, and myokine.
FGF21 Targeted tissues Functions Action manners Reference
Hepatokine WAT Lipid metabolism Endocrine (6)
Brain Glucocorticoid metabolism, physical
activity, circadian behavior
Endocrine (8)
Not identified Protection against dioxin toxicity Endocrine (9)
Adipokine WAT Thermogenesis Autocrine/paracrine (10)
Adiponectin induction Autocrine/paracrine (11, 12)
BAT Thermogenesis Autocrine/paracrine (13, 14)
Myokine WAT Energy metabolism, thermogenesis Endocrine (15, 16)
Skeletal muscle Insulin resistance Autocrine/paracrine (17)
Heart Cardiac protection Autocrine/paracrine (18)
WAT, white adipose tissue; BAT, brown adipose tissue.
serum FGF21 levels. Its toxicity was enhanced in Fgf21 knock-
out mice, indicating that FGF21 protect against this toxicity
(Table 1) (9).
FGF21 AS AN ADIPOKINE
Uncoupling protein 1 (UCP1) releases chemical energy as heat
in brown adipocytes. Beige adipocytes, brown adipocyte-like cells,
are UCP1-positive adipocytes in white adipose tissue (WAT). Beige
adipocytes markedly accumulated in subcutaneous WAT follow-
ing cold exposure (20). Cold exposure induced Fgf21 expression
in WAT expressing Fgfr1c and β-Klotho. The accumulation of
beige adipocytes was impaired in Fgf21 knockout mice, indicat-
ing that FGF21 induces the accumulation of beige adipocytes in
WAT in an autocrine/paracrine manner (Table 1) (10). Cold expo-
sure also induced Fgf21 expression in brown adipocytes expressing
Fgfr1c and β-Klotho. FGF21 also activates brown adipocytes in
an autocrine/paracrine manner (Table 1) (13, 14). In humans,
cold exposure increased circulating FGF21 levels, which acti-
vated brown adipocytes and enhanced lipolysis and thermoge-
nesis response through browning of WAT (21, 22). Thus, FGF21
activates the thermogenic machinery against hypothermia.
The systemic administration of FGF21 had no effect on metab-
olism in lipodystrophic mice with a WAT deficiency. However,
the administration of FGF21 was effective in these mice follow-
ing the transplantation of WAT (23). Thus, WAT is the pre-
dominant site that confers the metabolic activities of FGF21.
Adiponectin, an adipokine produced in WAT, controls systemic
glucose and lipid homeostasis in the liver and skeletal muscle in
an endocrine manner. FGF21 has many functional similarities to
adiponectin. Furthermore, FGF21 produced in WAT enhanced the
expression of adiponectin in WAT as well as serum adiponectin
levels. Several therapeutic benefits of FGF21 were impaired in
adiponectin knockout mice. The effects of FGF21 on the atten-
uation of obesity-induced impairments in insulin signaling in
the liver and skeletal muscle were also impaired in adiponectin
knockout mice. Thus, adiponectin acts as a downstream effector
of FGF21 in WAT and mediates the effects of FGF21 on energy
metabolism and insulin sensitivity in the liver and skeletal mus-
cle (Table 1) (11, 12). Insulin resistance develops in insulin-
responsive tissues due to the aberrant accumulation of intracellu-
lar lipids including the sphingolipid ceramide. FGF21 diminished
the accumulation of ceramides in obese animals. Changes in
energy expenditure and the ceramide-lowering effects induced by
FGF21 were impaired in adiponectin knockout mice. Thus, the
FGF21–adiponectin–ceramide axis controls energy expenditure
and insulin action (12).
FGF21 AS A MYOKINE
The PI3K/Akt1 pathway has been implicated in insulin signaling
and cellular hypertrophy. Skeletal muscle fiber hypertrophy was
observed in skeletal muscle-specific Akt1 transgenic mice. The
expression of Fgf21 in the muscle and serum FGF21 levels was
increased in the Akt1 transgenic mice (24). Thus, skeletal muscle
is also a source of FGF21, the expression of which is regulated by
a PI3K/Akt1 signaling pathway-dependent mechanism.
FGF21 is also known to be a myokine that is induced by dif-
ferent kinds of stress (19). Cytoplasmic constituents are delivered
to lysosomes for the degradation of aggregated proteins and recy-
cling of organelles or nutrients by autophagy. The amino acids
produced by autophagy are used for energy production or other
purposes during nutrient deficiencies. Mitochondrial dysfunc-
tion in autophagy-related 7 (Atg7 ) knockout mice increased Fgf21
expression by activating transcription factor 4 (Atf4), a master
regulator of the integrated stress response (15). An autophagy
deficiency and subsequent mitochondrial dysfunction increased
the production of FGF21 as a myokine to promote protection
against diet-induced obesity and insulin resistance (Table 1). The
induction of Fgf21, resistance to diet-induced obesity, and ame-
lioration of insulin resistance were also observed in the livers of
mice with autophagy deficiencies (15).
Fgf21 was induced in the skeletal muscle of Ucp1 skele-
tal muscle-specific transgenic mice and resulted in significantly
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elevated serum FGF21 levels. The integrated stress response was
activated in the skeletal muscle of Ucp1 transgenic mice with-
out myopathy or a muscle autophagy deficiency. The browning of
WAT with lipolysis and respiratory capacity was also increased
in Ucp1 transgenic mice (16). Improved substrate metabolism
and increased longevity were also observed in Ucp1 transgenic
mice. Targeting mitochondrial function in cultured myoblasts by
treatments with respiratory chain inhibitors resulted in the activa-
tion of an integrated stress response associated with the increased
expression of Fgf21. In addition, white adipocytes cultured with
the serum of Ucp1 transgenic mice resulted in an increase in the
expression of Ucp1. These findings indicate that the production of
FGF21 is coupled to mitochondrial dysfunction and the activation
of an integrated stress response in skeletal muscle. Thus, FGF21
as a myokine exhibits effects that lead to the increased brown-
ing of WAT in an endocrine manner (Table 1) (16). A subgroup
of human immunodeficiency virus (HIV) patients is associated
with insulin resistance. Fgf21 expression in skeletal muscle, but not
serum FGF21 levels was increased in HIV patients with lipodys-
trophy and this was correlated to insulin resistance, indicating that
FGF21 is a myokine that may be correlated with insulin resistance
in an autocrine/paracrine manner (Table 1) (17).
Exaggerated cardiac hypertrophy and dysfunction were
observed in Fgf21 knockout mice in response to the infusion
of isoproterenol. Cardiomyocytes produced and secreted FGF21,
indicating that FGF21 is a myokine that may protect against cardiac
hypertrophy in an autocrine/paracrine manner (Table 1) (18).
FGF21 SINGLE NUCLEOTIDE POLYMORPHISMS AS RISK
FACTORS FOR DISEASES
The intake of dietary macronutrients is associated with an
increased risk of obesity and diabetes. A single nucleotide poly-
morphism (SNP) in the Fgf21 exon was correlated with the per-
centage of total caloric intake from protein and carbohydrate,
suggesting that FGF21 is a potentially susceptible gene for obe-
sity and diabetes (25). SNPs in the Fgf21 3′ non-coding region
were also associated with metabolic syndrome, obesity, and dia-
betes (26) (Table 2). These findings indicate that Fgf21 SNPs are
possibly related with metabolic diseases.
SERUM FGF21 LEVELS AS BIOMARKERS OF DISEASES
Coronary heart disease (CHD) with a narrowing of the small blood
vessels in the heart could lead to heart attacks. Serum FGF21
levels were significantly higher in CHD patients, and were even
higher in CHD patients with diabetes, and hypertension. How-
ever, high serum FGF21 levels were associated with adverse lipid
profiles in CHD patients, indicating that this paradoxical increase
in CHD patients may reflect a compensatory response or resis-
tance to FGF21 (27). Carcinoid atherosclerosis typically results
in carotid stenosis. Serum FGF21 levels were positively corre-
lated with carotid intima-media thickness (IMT) in women (28).
Serum FGF21 levels were also significantly higher in patients with
both obesity and type 2 diabetes (29), in mitochondria disease
patients with dysfunctional mitochondria (30), in Cushing’s syn-
drome patients with prolonged and inappropriately high levels
of glucocorticoids (31), and in preeclampsia patients with seri-
ous cardiovascular complications in pregnancy (32). In contrast,
Table 2 | FGF21 as a risk factor for and biomarker of diseases.
FGF21 Diseases References
RISK FACTOR
SNP in the exon Dietary macronutrient intake (25)
SNPs in the 3′
non-coding region
Metabolic syndrome, obesity,
Type 2 diabetes
(26)
BIOMARKER
Increased serum levels Coronary heart disease (27)
Increased serum levels Carcinoid atherosclerosis (28)
Increased serum levels Obesity, type 2 diabetes (29)
Increased serum levels Mitochondrial disease (30)
Increased serum levels Cushing’s syndrome (31)
Increased serum levels Preeclampsia (32)
Decreased serum levels Anorexia nervosa (33)
SNP, single nucleotide polymorphism.
serum FGF21 levels were decreased in anorexia nervosa patients
with prominent reductions in body weight due to eating disorder
(33) (Table 2). These findings indicate that serum FGF21 levels
may be used as biomarkers of these diseases.
CONCLUSION
FGF21 acts in an FGFR-dependent manner with β-Klotho as a
cofactor. FGF21 with metabolic, but not proliferative activities has
unique functions. FGF21, which is typically induced by differ-
ent kinds of stress, plays various roles in energy metabolism and
injury protection as a hepatokine, adipokine, and myokine in an
endocrine or autocrine/paracrine manner. Fgf21 single polymor-
phisms are possibly related with metabolic diseases and FGF21
and biomarker of metabolic diseases. These findings provide new
insights into the physiological and pathophysiological roles of
FGF21.
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